GeneTether Therapeutics is an innovative genetic medicines company focused on creating best-in-class gene editing therapies based on our proprietary GeneTether™ platform.
Our platform is designed to increase the efficiency of genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs. We use a proprietary method to “tether” donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage.
Our Executive Team
GeneTether’s leadership consists of senior individuals with strong track records in building life sciences companies at all stages of growth.
Roland Boivin, BCom, MBA
Chief Executive Officer & Director
Mr. Boivin brings nearly 25 years of public company leadership experience, with a focus on strategic operations, finance, business development, and general management. Before joining GeneTether as CEO in 2021, he served as CFO at Medexus Pharmaceuticals, Inc. (formerly Pediapharm Inc.), a TSX-listed company focused on innovative rare disease treatment solutions. Among his many accomplishments in that role, Mr. Boivin led the company’s 2013 reverse takeover transaction, helped manage its graduation from the TSXV to the TSX, and played an integral role in its transformative acquisition of two speciality pharma companies. Prior to joining Medexus, Mr. Boivin was CFO at TSXV-listed Golden Hope Mines Limited. Previously, he held a variety of progressive positions at 3M Canada, including leading the company’s Consumer Division as Business Unit Manager, and was member of its Executive Committee. Mr. Boivin holds a Bachelor of Commerce in Marketing and Entrepreneurship from McGill University and an Executive MBA from Queen’s University.
R. Geoffrey Sargent, PhD
Chief Scientific Officer & Co-Founder
Dr. Sargent has been working in the field of gene editing in mammalian cells since 1987, beginning with his postdoctoral studies at the Imperial Cancer Research Fund (now Cancer Research UK) and Baylor College of Medicine. Dr. Sargent has worked in the Bay Area since 1998, directing academic and biotech company research programs focused on developing high efficiency gene editing technologies for human therapeutics and agricultural applications as well as human pluripotent stem cell applications. He teaches Biochemistry and Stem Cell Biology courses at UC Berkeley Extension and was previously a research scientist at UC San Francisco. Dr. Sargent earned his undergraduate degree in Applied Biology at Georgia Institute of Technology and his PhD in Biochemistry and Biophysics at Oregon State University.
Jean Jen, BBA, MPAcc, CPA, CA
Chief Financial Officer
Ms. Jen is a CPA, CA and has over twelve years of finance, accounting experience, working with both private and public companies in the life sciences sector. A highly sought-after consultant for early-stage biotechnology companies, Jean held various senior level positions as an independent financial consultant, and most recently held the role of Vice President of Finance at Anandia Laboratories, for which she was recognized as Accountancy Leader of the Year (Top 5 Nominee) by Women in Finance, Canada (2019). From 2013 to 2018, Jean held increasingly senior positions at Arbutus Biopharma Corp. (formerly Tekmira Pharmaceuticals Corp.), a Nasdaq-listed clinical-stage biopharma company with an expertise in liposomal drug delivery and RNA interference, where she helped in the Company’s growth to $1 billion in market cap. From 2009 to 2013, Ms. Jen worked in KPMG’s advisory and audit practices with a focus on publicly-listed companies. Jean holds a Bachelor of Business Administration degree from Simon Fraser University, as well as Master in Professional Accounting from the University of Saskatchewan.
Peter Sampson, BSc, MSc, PhD
Vice President, Research and Development
Peter has over 20 years of drug development experience including discovery chemistry, CMC regulatory affairs and IP portfolio management. Peter joined GeneTether from Scientus Pharma where he served as the Director of Research and Development at Scientus Pharma and led the advancement of their extraction technology through to commercialization. Prior to Scientus Pharma, Peter spent 10 years as a Scientist in the Therapeutics Group at the University Health Network (UHN) where he was involved in discovery research and led the CMC development programs for their PLK4, TTK and HPK1 clinical candidates. Prior to UHN, Peter held various R&D leadership roles of increasing responsibility at Affinium Pharmaceuticals, GlycoDesign Inc. and Albany Molecular Research Inc. Peter holds a BSc in Chemistry from St. Mary’s University and MSc and PhD degrees in Organic Chemistry from the University of Waterloo. He is the co-author of 20 scientific publications and an inventor on over 20 patents.
Kuldeep Neote, PhD
Chair, Scientific Advisory Board
Dr. Neote earned his PhD in Molecular Genetics at the University of Toronto. He has over 25 years in the life science industry, including as a researcher at Genentech, Pfizer, and Eli Lilly and Company, and as a business development executive at Johnson & Johnson and Eli Lilly and Company. He is currently an Entrepreneur-in-Residence at FACIT/OICR in Toronto and at The National Institutes of Health in Maryland.
Daren Graham, BBA, JD
Chairman & Co-Founder
Mr. Graham has nearly 20 years of experience in the life science industry as a merchant banker, senior operations executive, and corporate finance attorney. He is currently Chief Operating Officer of EGB Ventures. Previously he was a Co-Founder of Osteon Therapeutics, Managing Director of Allele Capital Partners, Executive Director in Tribal Capital Markets’ Equity Capital Life Sciences Division, and Chief Legal Officer and Vice President of Strategic Development at Sancilio Pharmaceuticals Company. Mr. Graham began his career as a corporate finance attorney in the Boston headquarters of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo PC, representing both private and public life science companies in private and public financings. After receiving a BBA in Finance from Northeastern State University of Oklahoma, Mr. Graham earned his Juris Doctorate from Boston College Law School. He is a member of the Massachusetts Bar and holds FINRA Series 7, 63 and 79 licenses.
William J. Garner, MD, MPH
Director & Co-Founder
Dr. Garner is a physician, investor and entrepreneur who has founded and co-founded numerous life science companies, including Race Oncology, Tryp Therapeutics, and Isla Pharmaceuticals, among others. In addition to serving as Founder and Managing Director of EGB Ventures, Dr. Garner has served in management roles and on the boards of a number of EGB Ventures portfolio companies. Prior to EGB, Dr. Garner held positions in the medical affairs division of Hoffmann LaRoche – Oncology and at a merchant banking firm in New York City. Dr. Garner earned his MD from New York Medical College and a Masters of Public Health from the Harvard T.H. Chan School of Public Health. He trained in the Anatomic Pathology residency program at Columbia-Presbyterian and is currently a licensed physician in the State of New York.
Andre Pereira Fraga Figueiredo is the founding partner of Aurea Holdings and has over 20 years of experience in M&A, Strategy and Business Development, first in the Petrochemical sector and later in the Renewable Energy sectors, operating in Europe, South America and Asia. In addition, he is an active investor in life science companies, participating in early-stages fund raising, as well as venture formation. Prior to founding Aurea Holdings, he was General Manager of Renovatio Group and Renovatio Eco-Solutions. He serves as a director of OnOn Holdings. Mr. Fraga obtained his undergraduate in Business Studies from Universidade Católica Portuguesa, holds an International MBA from Instituto de Empresa (IE) and has undertaken an Executive Education Program at Harvard Business School.
Mr. Jull is a co-founder and Chairman of Bordeaux Capital Inc., a Toronto-based mergers & acquisitions advisory firm focused on emerging companies in the natural resources and other sectors. Mr. Jull also holds the position of Executive Chairman for Arrow Exploration. He also acted as a Director and Chairman of the Special Committee for Aldridge Minerals Inc. Prior to Bordeaux Capital, Mr. Jull was a Managing Director, Corporate Finance at Mackie Research Capital Corp., an investment banking, and securities brokerage firm. Mr. Jull has experience working on numerous cross border equity and debt offerings involving energy assets around the world, with capital sourced in Canada, the U.S. and the U.K. At Prudential Bache Mr. Jull was the lead banker on the $40 million cross border Initial Public Offering of Quadra Logic Technologies a Vancouver based pharmaceutical company. He has completed over 200 financings and M&A transactions in the course of his career. Mr. Jull holds a BSc degree from the University of Toronto, an MBA from the University of Western Ontario, and PEng and CFA designations.